The dysregulation of ARL8B vesicular trafficking machinery has been implicated in therapeutic resistance and cancer pathogenesis [15], and is associated with an increased risk of disease recurrence in patients with prostate cancer. Here, ARL8B is linked to prostate carcinoma.